Roth Capital’s Yasmeen Rahimi is left bewildered, having banked on the success of OHRP’s wet-AMD asset, but holds out hope to become more positive on the stock down the line.
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
An article was published on Seeking Alpha detailing a long position.
